高盛:降上海医药(02607.HK)目标价至10.08港元 评级“沽售”

智通财经
Sep 04
【高盛:降上海医药(02607.HK)目标价至10.08港元 评级“沽售”】智通财经APP获悉,高盛发布研报称,上海医药(02607.HK)第二季销售额为708亿元人民币,同比升2.3%,低于预期,显示各细分市场持续疲软。剔除上海和记黄埔合并产生约17亿元人民币的一次性投资收益,第二季经常性净利润与控制良好的支出基本一致,但部分被毛利率下降所抵消,毛利率下降主要归因于制造业利润率的持续下降。该行将公司今年、明年及2027年盈利预测调整为升33.5%、降0.3%及降6.4%,其目标价由10.29港元下调至10.08港元,维持其“沽售”评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10